The group consider scientific issues surrounding the newer diabetes drugs. First, Jörn Schattenberg presented mode of action and research data on the two classes of drugs. After this, Wayne Eskridge asked questions from the patient perspective, Louise Campbell explores issues from a holistic perspective and Roger Green raised data points and concepts that arose in earlier episodes of the podcast.